Large-artery ischemic (clot-caused) strokes account for about 1 in 4 ischemic strokes, according to study author ángel Chamorro, M.D., Ph.D., professor of neurology at the University of Barcelona and head of the Comprehensive Stroke Center Hospital Clinic in Barcelona. These types of strokes can cause death and long-term disability because they block large arteries that supply blood to significant areas of the brain.

Initiée par le Ministère de la Recherche de l’Enseignement Supérieur et de l’Innovation, cette démarche est coordonnée par le Gircor, et fait écho à des initiatives similaires dans d’autres pays européens. En tant que signataire de cette Charte de transparence, la Société des Neurosciences s’engage à mieux informer le grand public sur l’utilisation d’animaux dans la recherche scientifique française en neurosciences.

Naox Technologies has become the first medtech company to receive FDA clearance for its in-ear EEG device that can negate the need for complex and limited scalp electrodes that have been used for brain monitoring for decades.Naox Link is an electroencephalography (EEG) platform that patients use via a small sensor worn in the ear, allowing brain activity to be monitored while they move around. According to a Jan. 6 release, the approach “enables long-duration, real-world brain monitoring beyond traditional hospital environments.”

Stroke is now the fourth leading cause of death in the US, with one person dying about every 3 minutes, according to the latest statistics. Over the past decade, several landmark trials have reshaped acute stroke care, including interventions for large vessel occlusion, thrombolysis, or endovascular thrombectomy (EVT), and streamlined hospital workflows.“The 2026 guidance brings that progress together to standardize stroke care across hospitals of all sizes and ensure rapid, evidence-based treatment for every patient, regardless of where they live,” the AHA/ASA noted. 

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that its holding subsidiary Neurovita has received market approval from the National Medical Products Administration (NMPA) for its AUCURA flow-diverting stent. This approval is for the treatment of adult patients with ruptured cystic or fusiform wide neck aneurysms (neck width ≥ 4mm or tumor/neck ratio < 2) of the internal carotid artery (from the petrous segment to the distal end) and vertebral artery, with a diameter of the tumor-carrying vessel ranging from 2.0mm to 6.0mm.

This study indicated a favorable midterm clinical outcome of the novel intracranial DES NOVA stent, with a low rate of ISR and without increasing the incidence of periprocedural complications in highly selected patients. The NOVA stent represents a promising new therapy to treat ICAS. However, the clinical results need to be further verified by larger sample size controlled studies with longer follow-up periods.

COMETIU is safe and effective for treating ICAS, with minimal risk during the procedure and a low rate of ISR during medium-term follow-up.

In patients with acute ischaemic stroke receiving reperfusion therapies such as mechanical thrombectomy (MT) or intravenous thrombolysis (IVT), an elevated neutrophil‑to‑lymphocyte ratio before treatment was associated with poor functional outcomes, whereas a higher lymphocyte‑to‑monocyte ratio was linked to better functional outcomes after MT.

Accurately predicting the prognosis of patients with acute ischemic stroke at discharge remains highly challenging after active treatment. The aim of this retrospective nationwide registry-based study was to identify key predictors associated with favorable outcomes and to develop machine learning models for patient outcome prediction.

L’accident vasculaire cérébral ischémique résulte de l’occlusion d’une artère intracrânienne, et son traitement nécessite une recanalisation artérielle rapide afin de rétablir la perfusion cérébrale. Les traitements actuels de recanalisation artérielle, la thrombolyse intraveineuse et la thrombectomie mécanique, ont amélioré le pronostic, mais leur faisabilité est restreinte et leur capacité à rétablir une bonne reperfusion cérébrale reste limitée. Des expériences dans des modèles animaux d’accident vasculaire cérébral ischémique, ainsi que des données cliniques, suggèrent que la thromboinflammation serait un facteur clé de résistance à ces traitements, non seulement en limitant l’efficacité de la thrombolyse intraveineuse, mais également en découplant recanalisation artérielle et reperfusion cérébrale.

In this study, we address the issue of whether applying transcranial magnetic and vibrotactile stimulation can improve the motor imagery BMI performance. Our findings provide evidence that applying transcranial magnetic stimulation with specified parameters (frequency 5 Hz, duration 6 min, 90% of the muscle activation threshold at rest) leads to preactivation of the occipital brain region and facilitates sensorimotor integration during motor imagery. We found that this process results in TMS-induced decrease of the motor imagery BMI latency. Integration of vibrotactile feedback in motor imagery BMI leads to enhancement of the BMI performance by an increase of the ERD level of EEG patterns over the contralateral motor cortex area corresponding to the MI of the non-dominant hand and an increase in motor cortical excitability.

To capture the damage in the artery induced by the stent, a gradient-enhanced damage model for arteries is implemented. It allows a detailed investigation of damage onset and evolution and proves to be numerically robust. Due to the modularity of the damage model, further characteristics of the artery such as prestretch, anisotropic behavior, and mass turnover can be readily incorporated.

A new study suggests that dementia may be driven in part by faulty blood flow in the brain. Researchers found that losing a key lipid causes blood vessels to become overactive, disrupting circulation and starving brain tissue. When the missing molecule was restored, normal blood flow returned. This discovery opens the door to new treatments aimed at fixing vascular problems in dementia.

The factors causing a surge in stroke cases during winter are a cold-induced rise in blood pressure, dehydration, and reduced activity. Experts emphasise awareness and preventive measures to protect at-risk individuals

Study in Lancet Digital Health represents the largest real-world evaluation of stroke AI imaging, encompassing data from more than 450,000 patients admitted to more than 100 NHS England hospitals over a 5-year period

According to a new study published in the New England Journal of Medicine, carotid artery stenting combined with medical therapy demonstrated a significantly lower stroke risk compared to intensive medical therapy alone in patients with severe asymptomatic carotid stenosis.

Intracranial atherosclerotic disease (ICAD) significantly contributes to ischemic stroke, especially among Asian populations. Large vessel occlusion (LVO) due to underlying ICAD accounts for 15–35% of acute ischemic stroke cases requiring endovascular therapy. However, the successful recanalization rate of ICAD-related LVO remains lower. The TG dilator is a self-expandable device, temporarily dilating ICAD-related blocked blood vessels.

In stroke due to basilar artery occlusion, the best technique to use for thrombectomy appears to depend on the underlying etiology of the clot, a new trial suggested. The Chinese ANGEL-COAST randomized trial compared two different techniques used for endovascular thrombectomy — either contact aspiration or stent retriever — in patients with basilar artery occlusion stroke. Results showed that using contact aspiration on the first attempt at clot removal achieved higher initial reperfusion rates without increasing the risk for symptomatic intracerebral hemorrhage or periprocedural complications.

Flow diversion is a transformative approach in neurointerventional surgery for intracranial aneurysms that relies heavily on effective antiplatelet therapy. The ideal approach, including the timing of treatment, the use of dual antiplatelet therapy (DAPT), and the number of flow-diverter devices to use, remains unknown. DAPT, which combines aspirin with a thienopyridine like clopidogrel, prasugrel, or ticagrelor, is the standard regimen, balancing thromboembolic protection and hemorrhagic risk. The variable response to clopidogrel, influenced by genetic polymorphisms, necessitates personalized treatment strategies. Alternatives like prasugrel and ticagrelor provide superior efficacy in specific scenarios but require careful consideration of bleeding risks and costs.

Despite growing evidence supporting the success of DAPT in reducing thromboembolic events, the lack of consensus on optimal regimens, doses, and duration is evident. Factors contributing to this variability include genetic polymorphisms affecting treatment response and ongoing debates regarding the clinical significance of hemorrhagic complications associated with DAPT.